Kolltan Pharmaceuticals

Antibody Oncology Therapeutics

Kolltan Pharmaceuticals, Inc. develops new generation monoclonal antibody oncology therapeutics. Its products are developed based in receptor tyrosine kinase. The company was founded in 2007 and is based in New Haven, Connecticut.

Founded in 2007
Total money raised: $80M

06511 300 George Street
Suite 530

New Haven